Evidence map›Paper›PMID 32996583›Full record

Trial reportCancer2020

Cognitive rehabilitation program to improve cognition of cancer patients treated with chemotherapy: A 3-arm randomized trial.

Mélanie Dos Santos, Isabelle Hardy-Léger, Olivier Rigal, Idlir Licaj, Sarah Dauchy, Christelle Levy, Sabine Noal, Carine Segura, Corinne Delcambre, Djelila Allouache and 9 more

Registry-linked trialOpen access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07755839 (CanCOG® - Cognitive Rehabilitation in Cancer), which is not on this map. Cited by 37 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 6 pooled it
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07755839 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

CanCOG® - Cognitive Rehabilitation in Cancer: A Protocol for a Multicenter Pilot Randomized Controlled Trial With Non-central Nervous System Cancer Survivors

TypeinterventionalSponsorAveiro UniversityRan2026 to 2028Enrolled60ConditionsCancer-related Cognitive Impairment, Cancer-related Cognitive Dysfunction, Cancer-related Cognitive Difficulties, Depression and Anxiety SymptomsArmsCanCOG® - Cogntive Rehabilitation in Cancer
3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 6 syntheses or guidelines pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Methodology of analysis of cognitive impairment in longitudinal randomized clinical trials in oncology: a scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Cognitive complaints in patients after cancer treatment: understanding oncologists' representations and management practices.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 2 countries.

Mélanie Dos SantosClinical Research Department, Centre François Baclesse, Caen, France.ORCID 0000-0002-1366-7678
Isabelle Hardy-LégerDepartment of Psycho-Oncology, Institut Gustave Roussy, Villejuif, France.
Olivier RigalDepartment of Medical Oncology, Centre Henri-Becquerel, Rouen, France.
Idlir LicajClinical Research Department, Centre François Baclesse, Caen, France.
Sarah DauchyDepartment of Psycho-Oncology, Institut Gustave Roussy, Villejuif, France.
Christelle LevyDepartment of Medical Oncology, Centre François Baclesse, Caen, France.
Sabine NoalDepartment of Medical Oncology, Centre François Baclesse, Caen, France.
Carine SeguraDepartment of Medical Oncology, Centre François Baclesse, Caen, France.
Corinne DelcambreDepartment of Medical Oncology, Centre François Baclesse, Caen, France.
Djelila AllouacheDepartment of Medical Oncology, Centre François Baclesse, Caen, France.
Aurélie ParzyDepartment of Medical Oncology, Centre François Baclesse, Caen, France.
Jérôme BarriereDepartment of Medical Oncology, Centre Antoine Lacassagne, Nice, France.
Thierry PetitDepartment of Medical Oncology, Centre Paul Strauss, Strasbourg, France.
Marie LangeClinical Research Department, Centre François Baclesse, Caen, France.ORCID 0000-0002-1749-2713
Aurélie CapelClinical Research Department, Centre François Baclesse, Caen, France.
Bénédicte ClarisseClinical Research Department, Centre François Baclesse, Caen, France.
Jean Michel GrellardClinical Research Department, Centre François Baclesse, Caen, France.
Johan LefelDepartment of Medical Oncology, Centre Henri-Becquerel, Rouen, France.
Florence JolyClinical Research Department, Centre François Baclesse, Caen, France.
Centre François Baclesse · FRInserm · FRInstitut Gustave Roussy · FRLaboratoire National Henri Becquerel · FRCentre Antoine Lacassagne · FRLevi Strauss (United States) · US

Funding

Ligue Contre le Cancer
6 · The paper itself

Abstract

backgroundThere is no treatment for cancer-related cognitive impairment, an important adverse effect that negatively impacts quality of life (QOL). We conducted a 3-arm randomized controlled trial to evaluate the impact of computer-assisted cognitive rehabilitation (CR) on cognition, QOL, anxiety, and depression among cancer patients treated with chemotherapy.

methodsPatients who reported cognitive complaints during or after completing chemotherapy were randomly assigned to 1 of 3 12-week CR programs: computer-assisted CR with a neuropsychologist (experimental group A), home cognitive self-exercises (active control group B), or phone follow-up (active control group C). Subjective cognition was assessed by the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog), objective cognition was assessed by neuropsychological tests, QOL was assessed by the FACT-General, and depression and anxiety were assessed by psychological tests. The primary endpoint was the proportion of patients with a 7-point improvement in the FACT-Cog perceived cognitive impairment (PCI) score.

resultsAmong the 167 enrolled patients (median age, 51 years), group A had the highest proportion of patients with a 7-point PCI improvement (75%), followed by groups B (59%) and C (57%), but the difference was not statistically significant (P = .13). Compared with groups B and C, the mean difference in PCI score was significantly higher in group A (P = .02), with better perceived cognitive abilities (P < .01) and a significant improvement in working memory (P = .03). Group A reported higher QOL related to cognition (FACT-Cog QOL) (P = .01) and improvement in depression symptoms (P = .03).

conclusionsThese results suggest a benefit of a computer-based CR program in the management of cancer-related cognitive impairment and complaints.

Indexed as

AdultAgedAntineoplastic AgentsCognitive DysfunctionFemaleFranceHumansMaleMiddle AgedNeoplasmsTherapy, Computer-AssistedTreatment OutcomeAntineoplastic Agentscancerchemotherapycognitive impairmentcognitive rehabilitationsupportive care

Identifiers

PMID32996583
PMCPMC7756299
OpenAlexW3090583663

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.